These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin. Lo Coco F; Ammatuna E; Noguera N Clin Adv Hematol Oncol; 2006 Jan; 4(1):57-62, 76-7. PubMed ID: 16562371 [TBL] [Abstract][Full Text] [Related]
4. Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide? Tsimberidou AM; Kantarjian H; Keating MJ; Estey E Leuk Lymphoma; 2006 Nov; 47(11):2282-8. PubMed ID: 17107899 [TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D; Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238 [TBL] [Abstract][Full Text] [Related]
6. The impact of molecularly targeted therapies upon the understanding of leukemogenesis and the role of hematopoietic stem cell transplantation in acute promyelocytic leukemia. Nagai S; Takahashi T; Kurokawa M Curr Stem Cell Res Ther; 2010 Dec; 5(4):372-8. PubMed ID: 20528759 [TBL] [Abstract][Full Text] [Related]
8. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642 [TBL] [Abstract][Full Text] [Related]
9. Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide. Slack JL; Waxman S; Tricot G; Tallman MS; Bloomfield CD Oncologist; 2002; 7 Suppl 1():1-13. PubMed ID: 11961204 [TBL] [Abstract][Full Text] [Related]
10. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia. Quezada G; Kopp L; Estey E; Wells RJ Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388 [TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide (trisenox) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation. Douer D; Hu W; Giralt S; Lill M; DiPersio J Oncologist; 2003; 8(2):132-40. PubMed ID: 12697938 [TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia. Chen L; Wang J; Hu X; Xu X Hematology; 2014 Jun; 19(4):202-7. PubMed ID: 24074286 [TBL] [Abstract][Full Text] [Related]
13. Successful unrelated bone marrow transplantation after arsenic trioxide treatment in a patient with relapsed acute promyelocytic leukemia. Mikoshiba M; Ohashi K; Takei N; Okuyama Y; Maeda Y; Hiruma K; Akiyama H; Fukuhara O; Takeshita A; Sakamaki H Int J Hematol; 2002 Jan; 75(1):104-6. PubMed ID: 11843281 [No Abstract] [Full Text] [Related]
14. Acute promyelocytic leukemia: where did we start, where are we now, and the future. Coombs CC; Tavakkoli M; Tallman MS Blood Cancer J; 2015 Apr; 5(4):e304. PubMed ID: 25885425 [TBL] [Abstract][Full Text] [Related]
15. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. Sanford D; Lo-Coco F; Sanz MA; Di Bona E; Coutre S; Altman JK; Wetzler M; Allen SL; Ravandi F; Kantarjian H; Cortes JE Br J Haematol; 2015 Nov; 171(4):471-7. PubMed ID: 26205361 [TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia. Leu L; Mohassel L Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784 [TBL] [Abstract][Full Text] [Related]
17. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. Lo-Coco F; Avvisati G; Vignetti M; Thiede C; Orlando SM; Iacobelli S; Ferrara F; Fazi P; Cicconi L; Di Bona E; Specchia G; Sica S; Divona M; Levis A; Fiedler W; Cerqui E; Breccia M; Fioritoni G; Salih HR; Cazzola M; Melillo L; Carella AM; Brandts CH; Morra E; von Lilienfeld-Toal M; Hertenstein B; Wattad M; Lübbert M; Hänel M; Schmitz N; Link H; Kropp MG; Rambaldi A; La Nasa G; Luppi M; Ciceri F; Finizio O; Venditti A; Fabbiano F; Döhner K; Sauer M; Ganser A; Amadori S; Mandelli F; Döhner H; Ehninger G; Schlenk RF; Platzbecker U; ; ; N Engl J Med; 2013 Jul; 369(2):111-21. PubMed ID: 23841729 [TBL] [Abstract][Full Text] [Related]
18. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation. Kitamura K; Kiyoi H; Yoshida H; Tobita T; Takeshita A; Ohno R; Naoe T Cancer Chemother Pharmacol; 1997; 40 Suppl():S36-41. PubMed ID: 9272132 [TBL] [Abstract][Full Text] [Related]